Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals faces stock volatility while pushing breakthrough CNS therapies for fibromyalgia and PTSD, balancing bold innovation against financial uncertainty.

Tonix Pharmaceuticals reports a loss but beats revenue expectations, highlighting promising FM and PTSD drug progress and potential upside for investors.

Tonix Pharmaceuticals (TNXP) explores CNS drug breakthroughs for fibromyalgia & PTSD amid volatile biotech markets—learn its pipeline, financial outlook, and investor updates.

Tonix Pharmaceuticals focuses on CNS disorders, with Phase 3 data on TONMYA™ for fibromyalgia and PTSD, while its stock reflects the volatile biotech market and investor hopes for breakthrough therapies.

Tonix Pharmaceuticals faces investor doubt as its stock plummets, lack of new milestones, and negative earnings raise concerns about future pain‑management prospects.

Tonix Pharmaceuticals (TNXP) gains 5% pre‑market as investors eye its CNS‑focused pipeline for fibromyalgia and PTSD, amid rising demand for precision therapies.

Tonix Pharmaceuticals is advancing CNS‑disorder therapies for fibromyalgia and PTSD, showing market resilience and investor confidence amid biotech volatility.

Tonix Pharmaceuticals reported Q1 2025 financial results, with a GAAP EPS of -$2.84 and revenue of $2.43 million, despite surpassing earnings expectations.